Local delivery of controlled-release simvastatin/PLGA /HA p microspheres enhances bone repair

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3895-3905

  Tai, I Chun ^a   Fu, Yin Chih ^a,b   Wang, Chih Kuang ^a,b   Chang, Je Ken ^a,b,c   Ho, Mei Ling ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

Author keywords

Bone fracture; Controlled release; Microspheres; Poly(lactic co glycolic acid); Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BONE MORPHOGENETIC PROTEIN 2; CREATINE KINASE; HYDROXYAPATITE; MICROSPHERE; OSTEOCALCIN; POLYGLACTIN; SIMVASTATIN; TRANSCRIPTION FACTOR RUNX2;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DEFECT; BONE REMODELING; CALLUS; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SYNTHESIS; ENCAPSULATION; FRACTURE; LOW DRUG DOSE; MOUSE; NONHUMAN; OSSIFICATION; PARTICLE SIZE; PH; PROTEIN EXPRESSION; SURFACE PROPERTY;

BONE FRACTURE; CONTROLLED RELEASE; MICROSPHERES; POLY(LACTIC-CO-GLYCOLIC ACID); STATIN;

ANIMALS; BONE REGENERATION; CAPSULES; DELAYED-ACTION PREPARATIONS; DIFFUSION; DURAPATITE; LACTIC ACID; MICE; MICE, INBRED BALB C; OSTEONECROSIS; POLYGLYCOLIC ACID; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84885764642     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S48694     Document Type: Article

References (39)

1. Yelin EH, Felts WR. A summary of the impact of musculoskeletal conditions in the United States. Arthritis Rheum. 1990;33:750-755.
2. Heckman JD, Sarasohn-Kahn J. The economics of treating tibia fractures. The cost of delayed unions. Bull Hosp Jt Dis. 1997;56:63-72.
3. Bax BE, Wozney JM, Ashhurst DE. Bone morphogenetic protein-2 increases the rate of callus formation after fracture of the rabbit tibia. Calcif Tissue Int. 1999;65:83-89.
4. Kandziora F, Bail H, Schmidmaier G, et al. Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors. J Neurosurg. 2002;97: 40-48.
5. Garrison KR, Donell S, Ryder J, et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess. 2007;11:1-150, iii-iv.
6. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976). 2006;31: 542-547.
7. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
8. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19: 117-125.
9. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.
10. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001;280:874-877.
11. Song C, Guo Z, Ma Q, et al. Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun. 2003;308:458-462.
12. 2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone. J Biol Chem. 2004;279:21239-21247.
13. Baek KH, Lee WY, Oh KW, et al. The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci. 2005;20:438-444.
14. Solomon DH, Finkelstein JS, Wang PS, Avorn J. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol Drug Saf. 2005;14: 219-226.
15. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol. 2001;21:1636-1641.
16. Ho ML, Chen YH, Liao HJ, et al. Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest. 2009;39: 296-303.
17. Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res. 2002;17:2004-2008.
18. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA. 2001;285:1850-1855.
19. Garrett IR, Gutierrez GE, Rossini G, et al. Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J Orthop Res. 2007;25: 1351-1357.
20. Lee Y, Schmid MJ, Marx DB, et al. The effect of local simvastatin delivery strategies on mandibular bone formation in vivo. Biomaterials. 2008;29:1940-1949.
21. Stein D, Lee Y, Schmid MJ, et al. Local simvastatin effects on mandibular bone growth and inflammation. J Periodontol. 2005;76:1861-1870.
22. Wang JW, Xu SW, Yang DS, Lv RK. Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporosis Int. 2007;18:1641-1650.
23. Skoglund B, Aspenberg P. Locally applied simvastatin improves fracture healing in mice. BMC Musculoskelet Disord. 2007;8:98.
24. Thylin MR, McConnell JC, Schmid MJ, et al. Effects of simvastatin gels on murine calvarial bone. J Periodontol. 2002;73:1141-1148.
25. Mukozawa A, Ueki K, Marukawa K, Okabe K, Moroi A, Nakagawa K. Bone healing of critical-sized nasal defects in rabbits by statins in two different carriers. Clin Oral Implants Res. 2011;22:1327-1335.
26. Ezirganli S, Kazancioglu HO, Mihmanli A, Aydin MS, Sharifov R, Alkan A. The effect of local simvastatin application on critical size defects in the diabetic rats. Clin Oral Implants Res. April 21, 2013. [Epub ahead of print.]
27. Nyan M, Sato D, Oda M, et al. Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect. J Pharmacol Sci. 2007;104:384-386.
28. Ho ML, Fu YC, Wang GJ, et al. Controlled release carrier of BSA made by w/o/w emulsion method containing PLGA and hydroxyapatite. J Control Release. 2008;128:142-148.
29. Wang CK, Ho ML, Wang GJ, et al. Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone. Biomaterials. 2009;30: 4178-4186.
30. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602-3609.
31. Cui Q, Wang GJ, Balian G. Steroid-induced adipogenesis in a pluripotential cell line from bone marrow. J Bone Joint Surg Am. 1997;79: 1054-1063.
32. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci. 1991;80: 830-834.
33. Chissas D, Stamatopoulos G, Verettas D, et al. Can low doses of simvastatin enhance fracture healing? An experimental study in rabbits. Injury. 2010;41:687-692.
34. Montagnani A, Gonnelli S, Cepollaro C, et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone. 2003;32:427-433.
35. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC; Geelong Osteoporosis Study. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002;162:537-540.
36. Tikiz C, Tikiz H, Taneli F, Gumuser G, Tuzun C. Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study. Clin Rheumatol. 2005;24: 447-452.
37. Fuentes I, Aguilera C. Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase. Med Clin (Barc). 1998;111:700. Spanish.
38. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 1998;81:368-369.
39. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA. 1997;277:296-297.